Aim To investigate clinical and prognostic associations of red cell distribution width (RDW) in hospitalized coronavirus disease 2019 (COVID-19) patients.

Methods We retrospectively analyzed the records of 3941 consecutive COVID-19 patients admitted to a tertiary-level institution from March 2020 to March 2021 who had available RDW on admission.

Results The median age was 74 years. The median Charlson comorbidity index (CCI) was 4. The majority of patients (84.1%) on admission presented with severe or critical COVID-19. Patients with higher RDW were significantly more likely to be older and female, to present earlier during infection, and to have higher comorbidity burden, worse functional status, and critical presentation of COVID-19 on admission. RDW was not significantly associated with C-reactive protein, occurrence of pneumonia, or need for oxygen supplementation on admission. During hospital stay, patients with higher RDW were significantly more likely to require high-flow oxygen therapy, mechanical ventilation, intensive care unit, and to experience prolonged immobilization, venous thromboembolism, bleeding, and bacterial sepsis. Thirty-day and post-hospital discharge mortality gradually increased with each rising RDW percent-point. In a series of multivariate Cox-regression models, RDW demonstrated robust prognostic properties at >14% cut-off level. This cut-off was associated with inferior 30-day and post-discharge survival independently of COVID-19 severity, age, and CCI; and with 30-day survival independently of COVID severity and established prognostic scores (CURB-65, 4C-mortality, COVID-gram and VACO-index).

Conclusion RDW has a complex relationship with COVID-19-associated inflammatory state and is affected by prior comorbidities. RDW can improve the prognostication in hospitalized COVID-19 patients.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a systemic infectious disease usually presenting with fever and respiratory symptoms (1). Although the most frequent serious manifestation of COVID-19 is pneumonia, the disease has been associated with cardiovascular, neurological, and gastrointestinal symptoms (2). Systemic inflammatory response mediated by high interleukin-6 concentrations induced by SARS-CoV-2 infection is associated with more severe clinical presentation, respiratory deterioration, and death (3,4). The presence of prior chronic comorbidities substantially affects the survival of COVID-19 patients (1).

Anisocytosis, ie, unequal red blood cells (RBC) size, is a sensitive marker of distress in erythropoiesis or RBC destruction. It can be induced by various metabolic and inflammatory stimuli, nutrient deficiencies, infections, spleen disorders, and specific drugs interfering with RBC production (5). Anisocytosis can be quantified as a coefficient of variation of mean cell volume termed red blood cell distribution width (RDW), which is obtained by automatic cell counters. Higher RDW levels have recently gained attention as they are uniformly associated with unfavorable presentation and inferior outcomes in many chronic metabolic and malignant diseases (6-12). More severe clinical presentation and higher mortality rates were also found in COVID-19 patients with higher RDW levels (13-16). However, an association of RDW with other clinical outcomes in hospitalized COVID-19 patients, as well as the relationship with increased mortality in the context of other established prognostic scores, are not well defined. Thus, we aimed to investigate clinical and prognostic significance of RDW in a large cohort of hospitalized COVID-19 patients from our institution. We hypothesized that RDW was associated with more severe COVID-19 on admission and higher death rate.

PATIENTS AND METHODS

We retrospectively analyzed the records of 3941 patients admitted to University Hospital Dubrava because of acute COVID-19 infection from March 2020 to March 2021. We included only patients who had available data on RDW on admission. During the pandemic, our institution was repurposed into a tertiary COVID-19 regional center treating patients with the most serious COVID-19 clinical presentation and COVID-19 patients with comorbidities who required immediate hospital level of care. All patients had a positive polymerase chain reaction or rapid antigen COVID-19 test before hospital admission. Patients were treated according to the contemporary guidelines. Only index hospital admissions for acute COVID-19 were investigated. Data were obtained from the hospital registry thorough an analysis of electronic and written medical records of 4014 COVID-19 patients. Seventy-three patients were excluded due to lack of available RDW data on admission. The study was approved by the University Hospital Dubrava Review Board (2021/2503-04).

RDW on admission was expressed as a coefficient of variation (%/100) of mean corpuscular volume (MCV) as reported by Advia 2120i automated cell counter (Siemens Medical Solutions Diagnostics Pte Ltd, Swords, Ireland). COVID-19 severity at admission was graded according the World Health Organization (WHO) recommendations and national guidelines (17,18) as mild, moderate, severe, and critical. Comorbidities, assessed as individual entities, were summarized by using the Charlson comorbidity index. Mortality and other clinical outcomes were assessed from the start of hospital stay.

Modified early warning score (MEWS) was used to quantify COVID-19 symptoms. Eastern Cooperative Oncology Group (ECOG) classification was used to estimate functional status on admission. Confusion, urea, respiratory rate, blood pressure, and 65 years of age (CURB-65); International Severe Acute Respiratory and emerging Infections Consortium 4C mortality score; COVID-gram; and Veterans Health Administration COVID-19 (VACO) index were used as prognostic risk scores. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used for the calculation of estimated glomerular filtration rate (eGFR).

The primary objective was to assess the clinical associations of RDW in the context of acute COVID-19 and its prognostic properties for investigated clinical outcomes. The secondary objectives were to assess the relationship with baseline clinical characteristics (both demographic and COVID-19-related), laboratory and radiologic features, and to establish appropriate optimized RDW cut-off levels to discriminate patient groups according to the risk of unwanted outcomes (30-day mortality, need for high flow oxygen therapy, need for mechanical ventilation, need for intensive care unit, arterial thromboses, venous thromboses, bleeding complications, bacterial sepsis, six-month post hospital discharge mortality, hospital-readmission).

Statistical methods

The normality of distribution of numerical variables was assessed with the Shapiro-Wilk test. The results
## TABLE 1. Patients' characteristics on admission and their relationship with red cell distribution width (RDW) stratified at median*†

| Characteristic                                      | Overall (N = 3941) | RDW≤14% (N = 1943) | RDW>14% (N = 1998) | P     |
|-----------------------------------------------------|--------------------|--------------------|--------------------|-------|
| **Age (years)**                                     | 74 (64-82)         | 71 (60-80)         | 77 (67-84)         | <0.001|
| Male sex                                            | 2215 (56.2)        | 1211 (62.3)        | 1004 (50.3)        | <0.001|
| **Reason for admission**                            | Overall <0.001     | Overall <0.001     | Overall <0.001     |       |
| Asymptomatic                                        | 92 (2.4)           | 42 (2.2)           | 52 (2.6)           | 0.364 |
| Pneumonia                                           | 2665 (67.6)        | 1416 (72.9)        | 1249 (62.5)        | <0.001|
| Temperature without pneum.                          | 124 (3.1)          | 59 (3)             | 65 (3.3)           | 0.697 |
| Acute medical condition                             | 503 (12.8)         | 175 (9)            | 328 (16.4)         | <0.001|
| Acute neurological condition                        | 176 (4.5)          | 88 (4.5)           | 88 (4.4)           | 0.849 |
| Acute surgical condition                            | 379 (9.6)          | 163 (8.4)          | 216 (10.8)         | 0.001 |
| Day of disease on admission                         | 5 (1-9)            | 6 (2-10)           | 3 (1-8)            | <0.001|
| ECOG status on admission                            | 3 (1-4)            | 2 (1-3)            | 3 (2-4)            | <0.001|
| Pneumonia                                           | 3485 (88.4)        | 3485 (88.4)        | 1756 (87.9)        | 0.281 |
| Oxygen therapy                                       | 3226 (81.9)        | 1577 (81.2)        | 1649 (82.5)        | 0.264 |
| MEWS score                                          | 2 (1-4)            | 2 (1-4)            | 2 (1-4)            | 0.357 |
| COVID-19 symptom severity                           | 423 (10.7)         | 198 (10.2)         | 225 (11.3)         | 0.278 |
| Mild                                                | 202 (5.1)          | 116 (6)            | 86 (4.3)           | 0.018 *|
| Moderate                                            | 2730 (69.3)        | 1368 (70.4)        | 1362 (68.2)        | 0.128 |
| Severe                                              | 586 (14.9)         | 261 (13.4)         | 325 (16.3)         | 0.012 |
| Critical                                            | 576 (14.6)         | 199 (10.2)         | 377 (18.9)         | <0.001|
| Other infection on admission                        | 4 (3-6)            | 4 (2-5)            | 5 (4-7)            | <0.001|
| Charlson comorbidity index                          | 5 (3-8)            | 4 (2-7)            | 6 (4-9)            | <0.001|
| Arterial hypertension                               | 2741 (69.6)        | 1283 (66)          | 1458 (73)          | <0.001|
| Diabetes mellitus                                    | 1185 (30.1)        | 547 (28.2)         | 638 (31.9)         | <0.001|
| Hyperlipoproteinemia                                 | 944 (24.0)         | 433 (22.3)         | 511 (25.6)         | <0.001|
| Obesity                                             | 1056 (26.8)        | 535 (27.5)         | 521 (26.1)         | 0.301 |
| Chr. heart failure                                   | 638 (16.2)         | 190 (9.8)          | 448 (22.4)         | <0.001|
| Atrial fibrillation                                  | 711 (18.0)         | 213 (11)           | 498 (24.9)         | <0.001|
| Coronary artery disease                             | 606 (15.4)         | 244 (12.6)         | 362 (18.1)         | <0.001|
| Previous CVI                                         | 460 (11.7)         | 168 (8.6)          | 292 (14.6)         | <0.001|
| Previous myocardial inf.                            | 363 (9.2)          | 146 (7.5)          | 217 (10.9)         | <0.001|
| Chr. kidney disease                                 | 486 (12.3)         | 121 (6.2)          | 365 (18.3)         | <0.001|
| COPD                                                | 281 (7.1)          | 97 (5)             | 184 (9.2)          | <0.001|
| Chronic liver disease                               | 110 (2.8)          | 34 (1.7)           | 76 (3.8)           | <0.001|
| Liver cirrhosis                                      | 49 (1.2)           | 4 (0.2)            | 45 (2.3)           | <0.001|
| Active malignancy                                    | 419 (10.6)         | 90 (4.6)           | 329 (16.5)         | <0.001|
| Metastatic malignancy                               | 273 (6.9)          | 49 (2.5)           | 224 (11.2)         | <0.01 |
| History of malignancy                               | 704 (179)          | 221 (11.4)         | 483 (24.2)         | <0.001|
| Dementia                                            | 814 (20.7)         | 298 (15.3)         | 516 (25.8)         | <0.001|
| Alcohol use                                          | 215 (5.5)          | 100 (5.1)          | 115 (5.8)          | 0.400 |
| Smoking                                              | 230 (5.8)          | 110 (5.7)          | 120 (6)            | 0.645 |
| IL-6 (pg/ml)                                         | 53.4 (20.9-121.8)  | 47.1 (17.5-106)    | 64.3 (24.9-149.4)  | 0.003 |
| Procalcitonin (ng/mL)                                | 0.22 (0.09-0.76)   | 0.17 (0.08-0.48)   | 0.3 (0.12-1.11)    | <0.001|
| WBC (x10^9/L)                                        | 8 (5.7-11.2)       | 7.8 (5.7-10.8)     | 8 (5.7-11.6)       | 0.039 |
| Hemoglobin (g/L)                                     | 128 (113-141)      | 135 (124-145)      | 119 (103-134)      | <0.001|
| MCV (fl)                                             | 88.9 (85.6-92.2)   | 89.2 (86.6-92.2)   | 88.4 (84.5-92.3)   | <0.001|
| MCHC (g/L)                                           | 333 (324-340)      | 336 (329-343)      | 329 (320-336)      | <0.001|
| Reticulocyte count (x10^9/L)                         | 53 (36-72.5)       | 38.5 (33-55)       | 55 (41-82.5)       | 0.022 |
| Platelets (x10^9/L)                                  | 220 (163-296)      | 223 (170-294)      | 217 (155-298)      | 0.009 |
are presented as median and interquartile range (IQR), and the groups were compared by using the Mann-Whitney U test or Kruskal-Wallis one-way analysis of variance (ANOVA) where appropriate. Jonckheere-Terpstra test for trend was used to assess the trend of increase in interleukin-6 concentrations across RDW categories. The receiver operating characteristic (ROC) curve analysis was used to define optimal cut-off values of RDW for clinical outcomes. Categorical variables are presented as frequencies and percentages, and were compared between the groups by using the X² test or the Fisher test where appropriate. Survival analyses were based on the Kaplan-Meier method. For univariate survival analyses, the Cox-Mantel version of the log-rank test and the Cox regression analysis were used. For multivariate analyses, the Cox regression analysis was used while simultaneously controlling for all included variables. P values <0.05 were considered statistically significant. All analyses were performed with MedCalc statistical software, version 20.008 (MedCalc Software Ltd, Ostend, Belgium).

RESULTS

The association of patients’ characteristics and RDW

The study enrolled 3941 hospitalized COVID-19 patients with available RDW values on admission (2215 or 56.2% men). The median age was 74 years; the median Charlson comorbidity index was 4 (IQR 3-6). The majority of patients (3316 or 84.1%) presented with severe or critical COVID-19 symptoms. During hospital stay, 901 (22.9%) patients required intensive care unit treatment, 768 (19.5%) required high-flow oxygen therapy, and 669 (17%) required mechanical ventilation. Thirty-day survival was 65.6%.

The median RDW was 14.1% (IQR 13.4-15.2). The optimal cut-off level for in-hospital and post-discharge survival discrimination defined by the ROC curve analysis was >14%. Patients’ characteristics stratified at this level are presented in Table 1. Patients with higher RDW were significantly more likely to be older, to be female, to present earlier in the disease course, and to have a worse functional status on admission. Patients with higher RDW were more likely to be admitted to hospital due to an acute medical or surgical condition as a leading reason and were less likely to be admitted due to pneumonia itself. Although patients with higher and lower RDW had a similar frequency of radiological pneumonia and need for oxygen supplementation, patients with higher RDW were more likely to have critical severity of symptoms and to have other infection on admission (P<0.05 for all analyses).

Charlson comorbidity index was significantly higher in patients with higher RDW, with higher RDW being associated with arterial hypertension, diabetes mellitus, hyperlipoproteinemia, chronic heart failure, atrial fibrillation, coronary artery disease, history of cerebrovascular insult, history of myocardial infarction, chronic kidney disease, chronic obstructive pulmonary disease, chronic liver

### TABLE 1. Patients’ characteristics on admission and their relationship with red cell distribution width (RDW) stratified at median*

| Parameter | Overall (N=3941) | RDWs<14% (N=1943) | RDWs>14% (N=1998) | P |
|-----------|-----------------|-------------------|-------------------|---|
| CRP (mg/L) | 88.3 (39.4-150.8) | 88.2 (37.3-148.4) | 88.5 (40.8-152.2) | 0.312 |
| Ferritin (μg/L) | 711 (386-1290) | 808 (450-1384) | 611 (310.5-1166.5) | <0.001 |
| D-dimers (mg/L FEU) | 1.42 (0.73-3.58) | 1.15 (0.63-2.64) | 1.75 (0.87-4.24) | <0.001 |
| eGFR (ml/min/1.73 m²) | 71.5 (45.8-90.3) | 79.7 (58.6-93.3) | 60.6 (34.6-85.6) | <0.001 |
| LDH (U/L) | 335 (248-454) | 345.5 (254-463) | 327 (242-443) | 0.008 |
| AST (U/L) | 41 (18-64) | 43 (30.8-66) | 39 (26-61) | <0.001 |
| ALT (U/L) | 31 (19-52) | 35 (23-59) | 26 (16-44) | <0.001 |
| GGT (U/L) | 42 (24-82) | 44 (26-79) | 40 (22-84) | 0.017 |
| ALP (U/L) | 72 (56-97) | 66 (53-86) | 79 (59-110) | <0.001 |
| Total bilirubin (μmol/L) | 11.4 (8.6-15.9) | 11.3 (8.8-14.9) | 11.6 (8.5-17.3) | 0.044 |
| Albumin (g/L) | 32 (28-35) | 33 (30-35) | 30 (27-34) | <0.001 |
| PT (%) | 100 (89-109) | 102 (93-110) | 97 (85-107) | <0.001 |

*Abbreviations: RDW – red cell distribution width; IQR – interquartile range; ECOG – Eastern Cooperative Oncology Group; MEWS – Modified Early Warning Score; nm. – number; chr. – chronic; CVI – cerebrovascular insult; inf. – infarction; COPD – chronic obstructive pulmonary disease; WBC – white blood cells; MCV – mean corpuscular volume; MCHC – mean corpuscular hemoglobin concentration; CRP – C-reactive protein; eGFR – estimated glomerular filtration rate; LDH – lactate dehydrogenase; AST – aspartate aminotransferase; ALT – alanine aminotransferase; GGT – gamma-glutamyl transferase; ALP – alkaline phosphatase; PT – prothrombin time.

†Data are n (%) or median (interquartile range). For comparison of numerical and categorical variables between lower and higher RDW groups the Mann-Whitney U and the Χ² test or the Fisher test were used, respectively.
disease, liver cirrhosis, active malignancy, metastatic malignancy and dementia (P < 0.05 for all analyses).

RDW was not significantly associated with C-reactive protein but was significantly associated with higher interleukin-6, which gradually increased with rising RDW percent points (P < 0.001 for trend of increase and P = 0.003 for overall difference in interleukin-6 between the categories) (Figure 1). Higher RDW was significantly associated with higher white blood cells, lower hemoglobin, lower MCV, lower mean corpuscular hemoglobin concentration, higher reticulocyte count, lower platelets, higher procalcitonin, lower ferritin, higher D-dimer, lower eGFR, lower lactate dehydrogenase, lower aspartate aminotransferase, lower alanine aminotransferase, lower gamma-glutamyl aminotransferase, higher alkaline phosphatase, higher total bilirubin, lower albumin, and lower prothrombin time (P < 0.05 for all analyses).

The associations of RDW with clinical outcomes during and after hospital stay

Associations of RDW with clinical outcomes are presented in Table 2. The median length of hospital stay was 10 days and did not significantly differ between patients with lower and higher RDW. Although patients with RDW > 14% and ≤ 14% (cut-off optimized for survival discrimination) had similar frequencies of intensive care unit use, high flow oxygen therapy and mechanical ventilation use, arterial and venous thrombotic events, and bacteriemia, we established significant associations of RDW with clinical outcomes during and after hospital stay.

**TABLE 2.** Clinical outcomes of index coronavirus disease-2012 hospital stay and post-hospital discharge in relationship to red cell distribution width (RDW)*

| Outcome                                      | Overall (N = 3941) | RDW≤14% (N = 1943) | RDW>14% (N = 1998) | P     |
|----------------------------------------------|--------------------|---------------------|---------------------|-------|
| Length of hospitalization (days)             | 10 (6-16)          | 10 (6-16)           | 10 (6-16)           | 0.329 |
| Intensive care unit                         | 901 (22.9)         | 448 (23.1)          | 453 (22.7)          | 0.774*|
| High-flow oxygen therapy                    | 768 (19.5)         | 401 (20.6)          | 367 (18.4)          | 0.072*|
| Mechanical ventilation                      | 669 (17)           | 314 (16.2)          | 355 (17.9)          | 0.179*|
| Immobilization ≥7 days                      | 1753 (44.5)        | 760 (39.1)          | 993 (49.7)          | <0.001*|
| Venous thromboembolism                      | 212 (5.4)          | 102 (5.2)           | 110 (5.5)           | 0.713*|
| Pulmonary embolism                          | 143 (3.6)          | 77 (4)              | 66 (3.3)            | 0.268 |
| Deep venous thrombosis                      | 85 (2.2)           | 35 (1.8)            | 50 (2.5)            | 0.129*|
| Arterial thrombosis                         | 228 (5.8)          | 109 (5.6)           | 119 (6)             | 0.648 |
| Acute myocardial infarction                 | 67 (1.7)           | 30 (1.5)            | 37 (1.9)            | 0.455 |
| Acute cerebrovascular insult                | 108 (2.7)          | 59 (3)              | 49 (2.5)            | 0.262 |
| Bleeding                                     | 318 (8.1)          | 126 (6.5)           | 192 (9.6)           | <0.001*|
| Major bleeding                               | 126 (3.2)          | 42 (2.2)            | 84 (4.2)            | <0.001*|
| Gastrointestinal bleeding                   | 132 (3.3)          | 41 (2.1)            | 91 (4.6)            | <0.001*|
| Bacterial sepsis                            | 390 (9.9)          | 186 (9.6)           | 204 (10.2)          | 0.503*|
| 30-day survival rate, %                     | 65.6               | 75.7                | 55.8                | <0.001*|
| Hospital readmission§                        | 76 (3)             | 33 (2.3)            | 43 (3.9)            | 0.016*|
| 6-month post-discharge survival rate§, %    | 91.6               | 95.5                | 86.1                | <0.001*|

*Statistically significant at level P < 0.05.
†Significant difference at level P < 0.05 on optimized RDW cut-off level (intensive care unit RDW > 13.1%, high flow oxygen therapy RDW > 13.1%, mechanical ventilation RDW > 13.1%, venous thromboembolism RDW > 14.9%, deep venous thrombosis RDW > 14.8%, bacterial sepsis RDW > 12.9%).
‡Data are n (%) or median (interquartile range), unless otherwise specified. For comparison of numerical and categorical variables between lower and higher RDW groups the Mann-Whitney U and the Χ² or the Fisher test were used, respectively. Survival was compared by using the log-rank test.
§Evaluated only in index hospitalization survivors (N = 2545).
lished optimized cut-off points for specific outcomes with ROC curve analysis. Patients with RDW at the cut-off level of >13.1 were significantly more likely to need high-flow oxygen therapy (20.2% vs 16.4%; \(P = 0.021\)), mechanical ventilation (18.1% vs 11.7%; \(P < 0.001\)), and intensive care unit (23.9% vs 17.9%; \(P < 0.001\)). Patients with RDW >13.8% were significantly more likely to experience prolonged immobilization for >7 days without bathroom privileges (49.1% vs 38.3%; \(P < 0.001\)). Regarding venous thromboembolism, higher RDW was significantly associated with venous thrombotic events (6.7% vs 4.8% for RDW >14.9% vs \(\leq 14.9\%\); \(P = 0.015\)) driven by a difference in the frequency of deep venous thromboses (3.3% vs 1.6% for RDW >14.8% vs \(\leq 14.8\%\); \(P < 0.001\)). However, no relevant cut-off was established for pulmonary embolism or arterial thrombotic events. Regarding bleeding complications, higher RDW was significantly associated with documented bleeding (10.6% vs 6.8% for RDW >14.7% vs \(\leq 14.7\%\); \(P < 0.001\)), namely bleeding from the gastrointestinal tract (6.7% vs 2.5% for RDW >15.5% vs \(\leq 15.5\%\); \(P < 0.001\)) and major bleeding events (4.2% vs 2% for RDW >13.9% vs \(\leq 13.9\%\); \(P < 0.001\)). Patients with RDW >12.9% compared with those with RDW \(\leq 12.9\%\) were significantly more likely to experience bacterial sepsis (10.3% vs 6.7%; \(P = 0.017\)).

Considering survival outcomes, patients with RDW >14% experienced a significantly lower 30-day survival rate (55.8% vs 75.7%; hazard ratio [HR] 2.14; \(P < 0.001\)) and a lower 6-month post-hospital discharge survival rate (86.1% vs 95.5%; HR 3.11; \(P < 0.001\)). With each rising percent point of RDW on admission, we observed gradually worsening 30-day survival and post-hospital discharge survival (Figures 2A and 2B). Patients having RDW 13%-13.9%, 14%-14.9%, 15%-15.9%, and \(\geq 16\%\) in comparison with those having RDW <13% had HR 1.79 (\(P < 0.001\)), HR 2.76 (\(P < 0.001\)), HR 3.42 (\(P < 0.001\)), and HR 4.12 (\(P < 0.001\)) for 30-day survival, respectively. They also had HR 2.03 (\(P = 0.056\)), HR 4.72 (\(P < 0.001\)), HR 4.78 (\(P < 0.001\)), and HR 6.06 (\(P < 0.001\)) for post-discharge survival, respectively.

In a series of multivariate Cox regression models, we demonstrated robust independent prognostic properties of RDW for survival. RDW remained significantly associated with 30-day survival in the Cox regression model adjusted for age, sex, COVID-19 symptom severity, and Charlson comorbidity index (RDW >14% HR = 1.62, \(P < 0.001\); age HR = 1.04, \(P < 0.001\); male sex HR = 1.12, \(P < 0.001\); COVID-19 severity moderate vs mild \(P = 0.669\); COVID-19 severity severe vs mild HR = 9, \(P > 0.001\); COVID-19 severity critical vs mild HR = 22.63, \(P < 0.001\); Charlson comorbidity index HR = 1.11, \(P < 0.001\)). Similarly, RDW remained significantly associated with post-hospital discharge mortality in the Cox regression model adjusted for age, sex, COVID-19 severity, and Charlson comorbidity index (RDW >14% HR = 2.01, \(P < 0.001\); age HR = 1.05, \(P < 0.001\); male sex HR = 0.708; COVID-19 severity moderate vs mild \(P = 0.987\); COVID-19 severity severe vs mild HR = 0.523; COVID-19 severity critical vs mild HR = 2.5, \(P = 0.001\); Charlson comorbidity index HR = 1.22, \(P < 0.001\)). RDW remained significantly associated with 30-day survival after adjusting for COVID-19 severity and COVID-19 prognostic scores CURB-65, 4C mortality, COVID gram, and VACO index (RDW >14% HR = 1.45, \(P < 0.001\); COVID-19 severity categories HR = 1.77, \(P < 0.001\); CURB-65 categories HR = 1.39, \(P < 0.001\); 4C mortality cate-

![FIGURE 2. (A) Survival at 30-days from hospital admission and (B) post-hospital-discharge survival stratified according to the red cell distribution width (RDW) percent point categories.](www.cmj.hr)
higher interleukin-6 concentrations, which increased with inflammatory state. Despite a significant association with RDW has a complex relationship with COVID-19-associated sive care and more advanced respiratory support.

higher RDW were significantly more likely to develop respi nia and respiratory insufficiency at baseline, patients with served in our study. Despite similar frequency of pneumo rd and respiratory insufficiency at baseline, patients with functon of chronic comorbidities might predispose to higher obiother acute and metastatic malignancy, and dementia. Interestingly, patients with higher RDW significantly grouped only among patients with critical COVID-19 on admission, and no similar association of RDW was observed with either radiological presence of pneumonia or the need for oxygen supplementation. Thus, the men tion chronic comorbidities might predispose to higher functional impairment and critical clinical presentation ob served in our study. Despite similar frequency of pneumo nia and respiratory insufficiency at baseline, patients with higher RDW were significantly more likely to develop respir atory deterioration during hospital stay and to need intensive care and more advanced respiratory support.

RDW has a complex relationship with COVID-19-associated inflammatory state. Despite a significant association with higher interleukin-6 concentrations, which increased with an increase in RDW percent points, RDW was not significa ntly associated with CRP concentration on admission. In addition, RDW was significantly associated with higher WBC, higher procalcitonin, higher D-dimer, lower albumin, lower prothrombin time, and higher bilirubin on admission, but also with lower liver transaminases, lower ferritin, and lower lactate dehydrogenase. This ambiguous inflammatory profile associated with higher RDW further implies that RDW elevation is affected by mechanisms oth er than acute inflammatory state associated with COVID 19. The magnitude of RDW elevation occurring in acute COVID-19 infection is unknown, and high RDW, and consequently higher hazard of death, might represent a higher degree of chronic inflammation, a higher comorbidity burden, and a predisposition to worse clinical outcomes predating acute COVID-19. It was speculated whether pa tients with higher RDW might present later during disease course and thus represent more advanced inflammation (20). Our data suggest the opposite – patients with higher RDW were more likely to present earlier during disease course, and RDW might be elevated because of acutization of chronic medical conditions other than pneumonia due to active COVID-19 infection.

A number of studies and several large meta-analyses have confirmed potent prognostic properties of RDW for the survival of COVID-19 patients (13-16). Our study provides important novelty as it comprehensively assesses several important clinical outcomes and investigates how differ ent levels of RDW increase reflect on survival, both in univariate and multivariate context controlling for clinically relevant parameters. RDW on admission not only predicts short- and long-term survival but also predicts a wide range of unwanted clinical outcomes, such as the need for more intensive respiratory support, prolonged immobilization, deep venous thrombosis, bacterial sepsis, and bleeding. The ability of RDW to discriminate between different outcomes changes when using different cut-off levels. Lower cut-off values optimally predicted complications of infec tious diseases (bacterial sepsis and tendency for COVID-19 deterioration), whereas higher values optimally predicted venous thrombotic events. Although pronounced aniso cytosis reflects a worse prognosis for thrombotic and sep tic outcomes in COVID-19 patients, the precise mechanism underlying these processes is not completely clear (compared with the intuitive role of some other blood compone nts such as platelets in the same events [21]). Considering survival as the most important outcome, long-term and short-term prognostic properties of RDW are independent from COVID-19 severity on admission, age, and comorbidit ies. Additionally, RDW covers different parts of prognostic spectrum than WHO-defined COVID-19 severity catego ries: CURB-65, 4C mortality, COVID gram, and VACO index. Therefore, RDW might be very useful in assessing the prog nosis of hospitalized COVID-19 patients. Our results need
to be validated by future studies in independent samples and by using RDW to further extend prognostic scores.

Limitations of our study are single-center experience, retrospective study design, and the lack of longitudinal assessment of RDW values. Our results are representative of tertiary level institution, with a majority of patients being elderly, having severe or critical COVID-19, and having high comorbidity burden. The main strength of our study is a large sample of patients who were uniformly exposed to standardized diagnostic and therapeutic procedures. This gives the study high statistical power to assess clinical and prognostic associations of RDW in the context of hospitalized COVID-19 patients.

In conclusion, RDW has a complex relationship with COVID-19-associated inflammatory state and is profoundly affected by prior comorbidities. It has a good potential for improvement of prognostication of hospitalized COVID-19 patients.

Acknowledgment This article is a part of the project “Registar hospitalno liječenih bolesnika u Respiracijskom centru KB Dubrava”/“Registry of hospitalized patients in University Hospital Dubrava Respiratory center.”

Funding None.

Ethical approval given by the University Hospital Dubrava Review Board (2021/2503-04).

Declaration of authorship ML conceived and designed the study; ML, AJ, UI, NPZ, ES, HH, AA, JS, and NB acquired the data; all authors analyzed and interpreted the data; ML and CJ drafted the manuscript; critically revised the manuscript for important intellectual content; ML and OJ drafted the manuscript; critically revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests ML is a statistical editor in the Croatian Medical Journal. To ensure that any possible conflict of interest relevant to the journal has been addressed, this article was reviewed according to best practice guidelines of international editorial organizations. All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work; no financial relationships that could appear to have influenced the submitted work.

References

1 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-42. Medline:32091533 doi:10.1001/jama.2020.2648

2 Attawah AY, Scheraga RG, Bhimraj A, Biehl M, Hatipoglu U. Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372. Medline:33692022 doi:10.1136/bmj.n436

3 Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol. 2021. Medline:34264880 doi:10.1097/BOR.0000000000001822

4 Lucijanić M, Stojić J, Atić A, Ćikara T, Osmani B, Barbić-Jaman M, et al. Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients. Wien Klin Wochenschr. 2022. Medline:35038003 doi:10.1007/s00058-021-01999-5

5 Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52:86-105. Medline:25535770 doi:10.3109/10408363.2014.992064

6 Kust D, Lucijanic M, Urch K, Samija I, Celapi I, Kruljic L, et al. Clinical and prognostic significance of anisocytosis measured as a red cell distribution width in patients with colorectal cancer. QJM. 2017. Medline:28069908 doi:10.1093/qjmed/hcvw223

7 Lucijanic M, Pejsa V, Kacic O, Mitovic Z, Tomasovic-Loncaric C, Stoos-Veic T, et al. The degree of anisocytosis predicts survival in patients with primary myelofibrosis. Acta Haematol. 2016;136:98-100. Medline:27189016 doi:10.1159/000445247

8 Krečak I, Krečak F, Gverić-Krečak V. High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. Blood Cells Mol Dis. 2020;80:102368. Medline:31669934 doi:10.1016/j.bcmd.2019.102368

9 Jurin I, Trkulja V, Ajduk M, Letliovit T, Hadžibegović I. Red cell distribution width in acute pulmonary embolism patients: A simple aid for improvement of the 30-day mortality risk stratification based on the pulmonary embolism severity index. Heart Lung. 2019;48:436-45. Medline:30905389 doi:10.1016/j.healun.2019.02.006

10 Li N, Zhou H, Tang Q. Red Blood Cell Distribution Width: A Novel Predictive Indicator for Cardiovascular and Cerebrovascular Diseases. Dis Markers. 2017;2017:7089493. Medline:29038615 doi:10.1155/2017/7089493

11 Periša V, Zibar L, Sinčić-Petričević J, Knezović A, Periša I, Barbić J. Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study. Croat Med J. 2015;56:334-43. Medline:26321026 doi:10.3325/cmj.2015.56.334

12 Lucijanic M, Kreca J, Verstovsek S, Soric E, Galusic D, Holik H, et al. Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis. Ann Hematol. 2021. Medline:34825960 doi:10.1007/s00277-021-04724-4

13 Sarkar S, Kannan S, Khanna P, Singh AK. Role of red blood cell distribution width, as a prognostic indicator in COVID-19: A systematic review and meta-analysis. Reviews in Medical Virology. 2021:e2264-e. Medline:34091982 doi:10.1002/rmv.2264

14 Zinelu A, Mangoni AA. Red blood cell distribution width, disease severity, and mortality in hospitalized patients with SARS-CoV-2 infection: a systematic review and meta-analysis. J Clin Med. 2021;10. Medline:33466770 doi:10.3390/jcm10020286

15 Lee JJ, Montazerin SM, Jamil A, Jamil U, Marszalek J, Chuan...
ML, et al. Association between red blood cell distribution width and mortality and severity among patients with COVID-19: A systematic review and meta-analysis. J Med Virol. 2021;93:2513-22. Medline:33448439 doi:10.1002/jmv.26797

Lippi G, Henry BM, Sanchis-Gomar F. Red blood cell distribution is a significant predictor of severe illness in coronavirus disease 2019. Acta Haematol. 2021;144:360-4. Medline:32841949 doi:10.1159/000510927

World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Geneva: World Health Organization, 2020 2020. Report No.: Contract No.: WHO/2019-nCoV/clinical/2020.5.

Ministarstvo zdravstva Republike Hrvatske. Smjernice za liječenje oboljelih od COVID-19, verzija 1 od 8. rujna 2020. 2020.

Foy BH, Carlson JCT, Reiertsen E, Pardos IV, Pallares Lopez R, Palanques-Tost E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults With SARS-CoV-2 infection. JAMA Netw Open. 2020;3:e2022058. Medline:32965501 doi:10.1001/jamanetworkopen.2020.22058

Lucijanic M, Krecak I, Soric E, Sedinic M, Sabljić A, Derek L, et al. Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism. Blood Cancer J. 2021;11:189. Medline:34845183 doi:10.1038/s41408-021-00585-2